The pharmacokinetic profile of teicoplanin after single 3 mg/kg doses in adults with different degrees of renal failure was reviewed. The disposition of teicoplanin was adequately described by a three-compartment open pharmacokinetic model and it appears to be primarily related to the degree of renal function. Teicoplanin total body clearance was less and the terminal elimination half-life progressively prolonged in association with renal failure, but the. volume of distribution at steadystate did not change. Highly significant relationships between teicoplanin total body and renal clearance and creatinine clearance have been reported and serve as a basis for adjusting dosage in patients with renal failure. In patients on continuous ambulatory peritoneal dialysis teicoplanin, administered either intravenously or intraperitoneally, showed bidirectional exchange characteristics through the peritoneal membrane, although transfer from the systemic circulation to peritoneal fluid was consistently low. Haemodialysis made no significant contribution to total body clearance of teicoplanin. Guidelines for administration of teicoplanin in patients with renal failure are discussed.
Introduction
This article reviews pharmacokinetic data to characterize the kinetic profile of a single iv dose of teicoplanin in volunteers and patients with various degrees of renal failure. Teicoplanin's kinetic profile was also investigated after intraperitoneal (ip) administration in patients on continuous ambulatory peritoneal dialysis (CAPD).
The difficulties of correctly evaluating and standardizing data obtained under different experimental conditions and from different groups were in part circumvented, since all data presented were obtained by the same group of investigators.
Methods and subjects
Teicoplanin 3 mg/kg was injected intravenously over 2 min in 29 adult patients with various degrees of renal failure and five healthy volunteers. The same dose was given intraperitoneally to five adult patients on CAPD. Seven groups were defined, based on endogenous creatinine clearance (CLQJ determined at the time of screening, and on dialysis technique. The main details of the subjects and baseline renal function are reported in Table I . Plasma, urine and dialysate teicoplanin concentrations were determined by an agar diffusion method. Although the microbiological assay does not distinguish individual components of the teicoplanin complex, this is the technique currently employed to detect the whole potentially active substrate.
Data were analysed by application of a three-compartment open pharmacokinetic model system, in which elimination is from the central compartment (Traina & Bonati, 1984) . Parameter estimates were obtained by fitting or from standard methods (Gibaldi & Perrier, 1982) . Linear regression, t-test or analysis of variance (ANOVA) were the statistical analyses used (Rocchetti & Recchia, 1982) .
Results and discussion
Semilogarithmic plots of the time courses of mean plasma concentrations after iv injection are shown in Figure 1 . For each degree of renal failure close values were found for the between-groups zero-time intercepts and hybrid first-order rate constants associated with the rapidly equilibrating sites in peripheral compartments. The rapid distribution was supported by comparison of the hybrid first-order rate constants (A,, k 2 and A 3 ) and by the larger value of first-order transfer rate constants (k, 1 and k 21 ) compared with the first-order elimination rate constant (ki 0 ). In contrast, the terminal disposition rate constant (A 3 ) decreased significantly (P < 001) with the increase in renal impairment, whereas the plasma elimination half-life (t 1/2 A 3 ) increased with increasing renal failure, from an average of 45 h in healthy volunteers to 163 h in anuric patients.
Taking the mean residence time as one of the parameters reflecting the overall characteristics of the teicoplanin time-course curve, a profile close to half-life was found (Figure 2 Non-renal clearance was unaffected by renal impairment, whereas total urinary excretion of active teicoplanin averaged 65% of the administered dose in normal subjects, dropping significantly in the presence of renal insufficiency, suggesting that other routes of excretion or metabolism to inactive compounds may be major pathways of teicoplanin elimination in patients with severe renal failure. In addition, the total clearance and renal clearance of teicoplanin in volunteers and patients were both consistently less than the creatinine clearance, suggesting that besides non-renal elimination routes, either renal tubular reabsorption of the active drug or significant protein binding has to be taken into account.
CAPD is a technique now widely used for the treatment of end-stage renal disease. However, two of its main drawbacks are bacterial peritonitis (Rubin et al., 1980) and exit-site infections caused by Gram-positive bacteria (Fenton et al., 1981) . Teicoplanin may be useful in the management of these problems. The phannacokinetics of teicoplanin during CAPD have been evaluated after both iv (Traina et al., 1986) and ip (Traina, G. L., Gentile, M. G., Fellin, G., Rosina, R., Cavenaghi, L., Buniva, G. & Bonati, M., unpublished data) administration.
After iv administration of teicoplanin, elimination of the compound from plasma in CAPD patients was lower than in other patients and was about four times less than in subjects with normal renal function (Figure 4 ). In these patients, anuric or with very low creatinine clearance, on CAPD, peritoneal clearance was negligible (7% of CL), and did not affect the drug disposition profile. After ip administration, the drug appeared in the plasma within 15 min and about 70% of teicoplanin was absorbed from the peritoneal dialysis fluid during a single 6 h dwell time. The kinetic drug profile closely agreed with that after iv injection (Figure 4 ) and this suggested that teicoplanin has bidirectional exchange characteristics through the peritoneal membrane, although transfer from the systemic circulation to peritoneal fluid is low. This poor transfer has been reported for other compounds such as gentamicin, tobramycin, vancomycin, atenolol, ornidazole and cefotaxime, but it is not yet known why it happens. However, addition of teicoplanin to CAPD fluid may be a useful route of administration for treatment of peritonitis and exit site infections in these patients.
Only traces of teicoplanin were detected in the dialysate of patients on haemodialysis, suggesting that this procedure does not affect the kinetics of the drug and that teicoplanin is not removed from the body by haemodialysis. Estimates of elimination rate constant for the tenninal phase and terminal elimination half-life were close to those of patients undergoing CAPD or with low creatinine clearance (Figure 1) . Particular caution must be exercised in extrapolating in-vitro or in-vivo experimental findings to clinical indications, but it is worth noting that plasma concentrations exceeded the teicoplanin MIC against all sensitive micro-organisms tested (Parenti et al., 1978; Verbist & Hendrickx, 1982) for many hours after a single 3 mg/kg dose, independently of the degree of renal failure. No side effects were reported during or after teicoplanin administration. No local pain or irritation was observed or reported in any of the subjects. Laboratory test values at the end of the study were not significantly different from pre-study values.
A full search of the literature indicated that a large part of available knowledge comes from unpublished reports or abstracts of international communications, but little from full papers. However, a summary of detailed published studies is given in Table II , and agreement between them seems good.
Therapeutic implications
With any dosage regimen, the objective is to achieve efficacy without toxicity. How to do this it is a matter for debate, but potentially therapeutic teicoplanin plasma concentrations of about 10 mg/1 (range 7-5-15 mg/1) have been suggested (data on file, Gruppo Lepetit SpA).
Several approaches have been used in patients with impaired renal function to obtain a plasma concentration profile close to that of healthy subjects (Gibson, 1980; Dettli, 1983) . All assume the attainment of a steady state during stable renal function. Two methods in particular have been widely used for dose adjustment of aminoglycosides (Zaske, 1980) . The first involves reducing the dose while continuing to use a standard dosage interval. Since the V o of teicoplanin does not vary with renal function, a loading dose equal to the standard dose applicable for patients with normal renal function (400 mg iv) should be given. The reduced maintenance dose for uraemic patients can be calculated from the ratio between CL (or CL*) of patients and healthy subjects, thus: maintenance dose = CL patient/CL normal x 400 mg iv. Thus, at a constant dosage interval (one day), subjects with mild-moderate degree of renal insufficiency {CLQH 10-80 ml/min) should be given a half maintenance dose and patients with severe renal failure (CL CR < 10 ml/min) should be given a third of the dose for normal subjects (Figure 5(a) ). The second method of adjusting drug therapy for uraemic patients involves prolonging the interval between doses but continuing to use the same dose (400 mg iv). The adjusted dose interval can be calculated, thus: dose interval in uraemia = CL of nonnal/CL of patient x 1 day ( Figure 5(b) ).
Similar findings can be obtained from the usual pharmacokinetic relationships (Gibaldi & Perrier, 1982) or graphic estimates (Dettli, 1983; 1984) .
The above guidelines are much simplified, but preliminary findings in multiple dosage in volunteers Tjandramaga et al., 1986) and patients with renal failure (Domart et al., 1986) support the reliability of the schemes proposed. Since no change in disposition of teicoplanin was observed in patients on dialysis, the dosage regimen in these patients should be modified in the same way as for other uraemics.
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